STOCK TITAN

Ehave Inc Stock Price, News & Analysis

EHVVF OTC

Welcome to our dedicated page for Ehave news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on Ehave stock.

Ehave Inc (EHVVF) delivers cutting-edge mental health informatics solutions through its Ehave Connect platform, empowering clinicians with data-driven decision tools. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and market position.

Access verified press releases, partnership announcements, and operational developments related to ADHD care optimization and medical cannabis treatment validation. Our curated collection includes earnings reports, technology licensing updates, and regulatory milestones that shape Ehave's role in digital healthcare innovation.

Key content categories cover strategic collaborations with medical institutions, platform enhancement disclosures, and financial performance communications. Stay informed about initiatives integrating diagnostic analytics with patient management systems across mental health ecosystems.

Bookmark this page for direct access to primary source materials from Ehave's leadership team. Regularly updated content ensures timely awareness of developments impacting the company's growth in healthcare technology markets.

Rhea-AI Summary

Ehave, Inc. (EHVVF) has announced that its subsidiary, KetaDASH, will utilize precision medicine in psychedelic-assisted therapy through a partnership with HaluGen Life Sciences. This collaboration will employ a genetic testing kit to assess patients' genetic profiles and risk factors. The aim is to personalize treatment based on individual genetic variations, particularly focusing on gene mutations that influence responses to ketamine and other psychedelics. This innovative approach positions KetaDASH as a pioneer in integrating genetics into psychedelic therapy, enhancing patient outcomes and differentiating the company in a competitive market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
-
Rhea-AI Summary

Ehave, Inc. (OTC Pink: EHVVF) has disclosed its ownership of approximately 9,793,754 shares in Mycotopia Therapies, valued over $24 million. The company announced a triangular merger with Ei.Ventures, targeting completion by July 30, 2022. This merger aims to establish PSLY.COM, focusing on mental health solutions leveraging psychoactive compounds and technology. Ehave’s stake in Mycotopia is valued at over $0.10 per share, and the merger could potentially benefit shareholders by monetizing existing assets while integrating new opportunities in mental health therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Ehave, Inc. (OTC Pink: EHVVF) has announced its mobile application platform, MetaHealthU, will focus on understanding and curing hallucinogen-persisting perception disorder (HPPD). Partnering with the University of Melbourne, Ehave aims to collect data and biomarkers for HPPD research. The app empowers users to manage their health data securely, leveraging blockchain technology for improved privacy and efficiency. A pilot study for HPPD is set to begin in mid-2022. Ehave aims to lead in mitigating negative side effects of psychedelic treatments by analyzing genetic predispositions related to HPPD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19%
Tags
none
Rhea-AI Summary

Ehave, Inc. (OTC Pink: EHVVF) announced a partnership with Heally to enhance its KetaDASH platform. This collaboration will provide licensed psychotherapists and registered nurses for patients seeking alternative treatments like ketamine therapy. The KetaDASH service offers in-home psychedelic therapy sessions, connecting patients with professionals via Heally's telehealth portal. This move is seen as a response to rising mental health issues exacerbated by the COVID-19 pandemic, aiming to improve access to care and patient outcomes in the mental health sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
-
Rhea-AI Summary

Ehave, Inc. (OTC Pink: EHVVF) has licensed advanced AI technology from Vastmindz to enhance its MetaHealthU offerings. Set to monetize this technology in 2022, Ehave aims to integrate features in its Ehave Dashboard to monitor vital statistics such as Heart Rate and Oxygen Saturation through facial light absorption analysis. Vastmindz's CEO recently showcased their innovation on the Unicorn Hunters platform, a show with over 14.5 million viewers, receiving positive remarks from tech experts like Steve Wozniak. This partnership is positioned to broaden healthcare accessibility globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.89%
Tags
none
-
Rhea-AI Summary

Ehave, Inc. (EHVVF) has launched KetaDASH, a managed service offering in-home ketamine therapy for patients with treatment-resistant mental health issues. The service starts in the San Francisco Bay Area and Greater Sacramento Area, with plans to expand. KetaDASH focuses on safety and patient comfort, featuring a team of qualified professionals providing treatments after an initial telemedicine consultation. This initiative aims to broaden access to ketamine therapy, which has shown promise in treating conditions like depression and PTSD, thereby enhancing patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Ehave, Inc. (OTC Pink: EHVVF) announced the acquisition of Rejuv IV, enhancing its KetaDASH brand. This mobile IV therapy provider, active in the San Francisco Bay Area, offers services such as Ketamine treatments and IV Vitamin Therapy. CEO Ben Kaplan emphasized the company's commitment to mental health, highlighting KetaDASH’s role in providing lifesaving treatments for psychiatric disorders like depression and PTSD. The service combines at-home administration with telehealth supervision, expanding Ehave's reach in mental health therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
none
-
Rhea-AI Summary

Ehave, Inc. (EHVVF) shares insights in a letter to shareholders from CEO Ben Kaplan, highlighting advancements in digital therapeutics for mental health using psychedelics. The company emphasizes mental health issues affecting millions in the U.S. and aims to enhance treatments. Key developments from 2021 include a strengthened balance sheet and successful product development. With plans to monetize technology through licensing, Ehave anticipates significant growth. Additionally, Ehave will distribute 30% of PSLY.COM holdings to shareholders and targets launching the KetaDASH home delivery service soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.75%
Tags
none
-
Rhea-AI Summary

Ehave has signed a Letter of Intent (LOI) with Ei.Ventures to explore a merger forming PSLY.COM, an estimated $360 million transaction. As part of this process, Ehave plans to spin out 30% of its Mycotopia Therapies shares to existing shareholders. Ehave currently holds approximately 9.8 million shares of Mycotopia, which focuses on psilocybin-based therapeutics. The merged companies aim to list on NASDAQ after completing pre-clinical trials for their flagship product, Psilly. This move is seen as a strategic shift towards enhancing shareholder value and market presence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
82.67%
Tags
News
Rhea-AI Summary

Ehave, Inc. (EHVVF) announced its KetaDASH platform will sponsor the 2021 Psychedelic Investor Guide. KetaDASH is an IV-based home delivery service for ketamine therapy aimed at enhancing patient care. CEO Ben Kaplan highlighted the platform's HIPAA compliance and early market entry. The Investor Guide features 46 prominent companies in the psychedelic sector, providing essential investment data, including stock charts and financial information. This comprehensive guide will be updated monthly and aims to simplify research for investors in the rapidly developing psychedelic investment landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
none

FAQ

What is the current stock price of Ehave (EHVVF)?

The current stock price of Ehave (EHVVF) is $0.0025 as of July 3, 2025.

What is the market cap of Ehave (EHVVF)?

The market cap of Ehave (EHVVF) is approximately 719.1K.
Ehave Inc

OTC:EHVVF

EHVVF Rankings

EHVVF Stock Data

719.14k
321.11M
10.7%
Software - Application
Technology
Link
United States
Miami